Product nameAnti-HNF-1B antibody
See all HNF-1B primary antibodies
DescriptionRabbit polyclonal to HNF-1B
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
Synthetic peptide within Human HNF-1B aa 50-150 conjugated to keyhole limpet haemocyanin. The exact sequence is proprietary. (NP_000449)
Database link: P35680
- HEK293T cells transfected with pCMV6-ENTRY HNF-1B; Human liver carcinoma tissue.
Previously labelled as HNF1 beta.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.3
Preservative: 0.02% Sodium azide
Constituents: 1% BSA, 50% Glycerol, 48% PBS
Concentration information loading...
Our Abpromise guarantee covers the use of ab187744 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500. Predicted molecular weight: 61 kDa.|
FunctionTranscription factor, probably binds to the inverted palindrome 5'-GTTAATNATTAAC-3'.
Involvement in diseaseDefects in HNF1B are the cause of renal cysts and diabetes syndrome (RCAD) [MIM:137920]; also called maturity-onset diabetes of the young type 5 (MODY5) or familial hypoplastic glomerulocystic kidney disease (GCKD). RCAD is an autosomal dominant disorder comprising non-diabetic renal disease resulting from abnormal renal development, and diabetes, which in some cases occurs earlier than age 25 years and is thus consistent with a diagnosis of maturity-onset diabetes of the young (MODY5). The renal disease is highly variable and includes renal cysts, glomerular tufts, aberrant nephrogenesis, primitive tubules, irregular collecting systems, oligomeganephronia, enlarged renal pelves, abnormal calyces, small kidney, single kidney, horseshoe kidney, and hyperuricemic nephropathy.
Defects in HNF1B may be rare genetic risk factor contributing to the development of non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853]. NIDDM is characterized by an autosomal dominant mode of inheritance, onset during adulthood and insulin resistance.
Defects in HNF1B may be a cause of susceptibility to prostate cancer hereditary type 11 (HPC11) [MIM:611955]. It is a condition associated with familial predisposition to cancer of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
Sequence similaritiesBelongs to the HNF1 homeobox family.
Contains 1 homeobox DNA-binding domain.
- Information by UniProt
- FJHN antibody
- Hepatocyte nuclear factor 1 beta antibody
- Hepatocyte nuclear factor 1-beta antibody
All lanes : Anti-HNF-1B antibody (ab187744) at 1/500 dilution
Lane 1 : HEK293T cells transfected with pCMV6-ENTRY control
Lane 2 : HEK293T cells transfected with pCMV6-ENTRY HNF-1B
Lysates/proteins at 5 µg per lane.
Predicted band size: 61 kDa
HEK293T cell lysates were generated from transient transfection of the cDNA clone RC204453
Immunohistochemical analysis of paraffin embedded Human liver carcinoma tissue labeling HNF-1B with ab187744 at 1/150.
This product has been referenced in:
- Shaalan UF et al. Reduced Immunohistochemical Expression of Hnf1ß and FoxA2 in Liver Tissue Can Discriminate Between Biliary Atresia and Other Causes of Neonatal Cholestasis. Appl Immunohistochem Mol Morphol 27:e32-e38 (2019). Read more (PubMed: 29406331) »